テキサスにおける慢性骨髄性白血病の臨床試験
テキサス内の拠点で、慢性骨髄性白血病に関する18件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06817720Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07269470Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06236724Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- M D Anderson Cancer Center, Houston
被験者募集中第1相
1歳以上 · 全性別 · 2026/09/18更新 · NCT03630991Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1051, Amarillo
- Ascentage Investigative Site #1036, Austin
- Ascentage Investigative Site #1501, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06423911A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- 他5件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Asciminib Roll-over Study
- Texas Oncology, Dallas
- Uni Of TX MD Anderson Cancer Cntr, Houston
被験者募集中第4相
7歳〜100歳 · 全性別 · 2026/07/06更新 · NCT04877522Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/05/20更新 · NCT02115295Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中観察研究
全年齢 · 全性別 · 2026/04/16更新 · NCT00816114A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/01更新 · NCT05304377A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
被験者募集中第2相
18歳〜66歳 · 全性別 · 2026/03/17更新 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- MD Anderson Cancer Center, Houston
被験者募集中第1相
12歳以上 · 全性別 · 2026/03/16更新 · NCT06994676A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- The University of Texas M.D. Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/12更新 · NCT06163430Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/05更新 · NCT04260022TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2025/02/21更新 · NCT06088888ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。